186 related articles for article (PubMed ID: 28273450)
41. Targeting BRAFV600E in an inducible murine model of melanoma.
Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
[TBL] [Abstract][Full Text] [Related]
42. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
43. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
44. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
45. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
46. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
47. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
48. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
49. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
50. BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.
Kanitakis J; Baldassini S; Lora V; Euvrard S
Eur J Dermatol; 2010; 20(2):167-71. PubMed ID: 19919912
[TBL] [Abstract][Full Text] [Related]
51. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
52. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
[TBL] [Abstract][Full Text] [Related]
53. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
[TBL] [Abstract][Full Text] [Related]
54. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis.
De Luca A; Carpanese D; Rapanotti MC; Viguria TM; Forgione MA; Rotili D; Fulci C; Iorio E; Quintieri L; Chimenti S; Bianchi L; Rosato A; Caccuri AM
Oncotarget; 2017 Feb; 8(9):15520-15538. PubMed ID: 28107182
[TBL] [Abstract][Full Text] [Related]
55. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
56. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
57. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
[TBL] [Abstract][Full Text] [Related]
58. [Melanoma- finally good news].
Wicki A; Arnold AW; Itin PH; Zippelius A
Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
[TBL] [Abstract][Full Text] [Related]
59. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
[TBL] [Abstract][Full Text] [Related]
60. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.
Wolf Y; Bartok O; Patkar S; Eli GB; Cohen S; Litchfield K; Levy R; Jiménez-Sánchez A; Trabish S; Lee JS; Karathia H; Barnea E; Day CP; Cinnamon E; Stein I; Solomon A; Bitton L; Pérez-Guijarro E; Dubovik T; Shen-Orr SS; Miller ML; Merlino G; Levin Y; Pikarsky E; Eisenbach L; Admon A; Swanton C; Ruppin E; Samuels Y
Cell; 2019 Sep; 179(1):219-235.e21. PubMed ID: 31522890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
